SEC Form 4 · accession 0001104659-18-000890
Avalo Therapeutics, Inc. · AVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Isaac Blech
Director
Period of report
Dec 31, 2017
Accepted (ET)
Jan 5, 2018 · 9:17 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534120
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy) | $3.20 | Dec 31, 2017 | A | 8,267 | A | Dec 31, 2017 | Dec 30, 2027 | Common Stock | 8,267 | 8,267 | D |